China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Bilibili (Bili Us): Further Downside Risks Ahead

[Bilibili Inc. (BILI US) Target Price Change]: Minor Protection Would Be a Pending Issue

[Bilibili Inc. (BILI US, SELL, TP US$15.4)]: Long-Term Challenge Exists Amid Short-Term Catalysts

BILIBILI (BILI US): Can Achieving Breakeven Justify US$10bn Market Cap?

Bilibili Follow-On Offering - Seems Opportunistic

Bilibili Follow-On Offering: Limited Upside

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

China/Asia TMT

Shawn Yang

Equity Bottom-Up

<ul>
<li>While BILI's top line in 4Q22/2023 would be in line, we suggest that its bottom line in 4Q22/2023 would beat cons. by 6%/18% due to cost-savings and optimized monetization efficiency. </li>
<li>BILI’s adjusted net loss would be significantly narrowed to (3.2)bn RMB in 2023, per our estimation. However, we still have concerns about some of BILI’s fundamentals.</li>
<li>Maintain SELL but raise TP to US$ 16.4, implying 1.8X PS in 2023.</li>
</ul>


While BILI's top line in 4Q22/2023 would be in line, we suggest that its bottom line in 4Q22/2023 would beat cons. by 6%/18% due to cost-savings and optimized monetization efficiency. 
BILI’s adjusted net loss would be significantly narrowed to (3.2)bn RMB in 2023, per our estimation. However, we still have concerns about some of BILI’s fundamentals.
Maintain SELL but raise TP to US$ 16.4, implying 1.8X PS in 2023.


Bilibili(Bili.US) 4Q22 Preview: Raise TP for More Optimistic Outlook in 2023